Cardiologists are treating more and more patients with established cardiovascular disease and diabetes. Over the last decade, studies have shown that patients with diabetes are at greater risk of dying from cardiovascular disease than those without diabetes. Several important randomized trials show medical interventions in patients with diabetes can provide protective benefits. In the EMPA-REG OUTCOME trial, empagliflozin reduced the incidence of the composite endpoint of death from cardiovascular causes, nonfatal myocardial infarction or nonfatal stroke by 14 percent, while death from cardiovascular-related causes was reduced by 38 percent. Heart failure was also reduced by 35 percent. Read more about this study and other findings. Test your knowledge of the EMPA-REG OUTCOME trial with a poll from the Diabetes and Cardiometabolic Disease Clinical Topic Collection on ACC.org. In a recent video, Christopher Cannon, MD, FACC, discusses managing cardiovascular risk in patients with type 2 diabetes during ACC.17 in Washington, DC. Visit ACC.org/EMPA for more information.